Xuanzhu Biopharmaceutical Co., Ltd. (02575.HK)

Xuanzhu Biopharmaceutical Co., Ltd. engages in the research and development of chemical and biological drugs. The company is headquartered in Beijing, Beijing and currently employs 197 full-time employees. The company went IPO on 2025-10-15. The firm is primarily engaged in business of research and development, manufacturing and commercialization of innovative drugs, focusing on a number of therapeutic areas such as digestion, oncology and non-alcoholic steatohepatitis (NASH). The Company’s main products include KBP-3571, XZP-3287 and XZP-3621. The firm mainly conducts its businesses in the domestic market.